Sydnexis<\/a><\/strong>\u2019 ongoing expansion and growth.<\/p>\nErin will lead Sydnexis\u2019 market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, she brings a wealth of knowledge in leading ophthalmic product launches and building successful brands and teams. Prior to joining Sydnexis, Erin held prominent roles at several leading companies, including Iveric Bio (an Astellas Company), Aerie, Alcon, and Novartis.<\/p>\n
\u201cWe are thrilled that Erin has joined Sydnexis in pursuit of our mission. Erin brings a wealth of knowledge, expertise, and direct experience with market access customers and organizations that is unsurpassed in ophthalmology. She is a dynamic addition to the Sydnexis leadership team, and we are extremely excited for her future success,\u201d said Nick Ruth, Chief Commercial Officer at Sydnexis.<\/p>\n
“Joining the Sydnexis team presents an opportunity to help advance a treatment for pediatric progressive myopia and enhance the long-term quality of life of children,\u201d said Erin. \u201cI’m excited to create affordable access to a novel treatment that will serve a growing unmet need for children and their families. I look forward to working with this incredible team.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"
January 19, 2024 SAN DIEGO \u2014 Sydnexis announced that Erin Horn has been named the Vice President, Head of Market Access at the company. With a strong and diverse track record of commercial success in traditional and specialty ophthalmic pharmaceuticals, she will provide her market access, launch expertise, and commercial leadership to Sydnexis\u2019 ongoing expansion and growth. Erin will lead Sydnexis\u2019 market access, pricing, contracting, and go-to-market strategies. With 25 years of industry experience, she brings a wealth of knowledge in leading ophthalmic product launches and building successful brands and teams. Prior to joining Sydnexis, Erin held prominent roles at several leading companies, including Iveric Bio (an Astellas Company), Aerie, Alcon, and Novartis. \u201cWe are thrilled that Erin has joined Sydnexis in pursuit of our mission. Erin brings a wealth of knowledge, expertise, and direct experience with market access customers and organizations that is unsurpassed in ophthalmology. She is a dynamic addition to the Sydnexis leadership team, and we are extremely excited for her future success,\u201d said Nick Ruth, Chief Commercial Officer at Sydnexis. “Joining the Sydnexis team presents an opportunity to help advance a treatment for pediatric progressive myopia and enhance the long-term quality of life of children,\u201d said Erin. \u201cI’m excited to create affordable access to a novel treatment that will serve a growing unmet need for children and their families. I look forward to working with this incredible team.\u201d<\/p>\n","protected":false},"author":375,"featured_media":48555,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1733],"tags":[5050,3895,452,698,1067,1734,1584,4699,1727,5051],"yoast_head":"\n
Erin Horn Named VP, Head of Market Access at Sydnexis - Review of Myopia Management<\/title>\n \n \n \n \n \n \n \n \n \n \n \n\t \n\t \n\t \n \n \n \n\t \n\t \n\t \n